Related Experiment Video
Updated: Apr 21, 2026

Recurrent Herpetic Stromal Keratitis in Mice, a Model for Studying Human HSK
Published on: December 18, 2012
Human herpesvirus 6 involvement in paediatric drug hypersensitivity syndrome
J Ahluwalia1, K Abuabara, M J Perman
1Department of Pediatrics, Division of General Pediatrics, Section of Dermatology, The Children's Hospital of Philadelphia, 3550 Market Street, 2nd Floor, Philadelphia, 19104, PA, U.S.A.
Insights
Human herpesvirus 6 (HHV6) positivity in children with drug hypersensitivity syndrome (DHS) indicates a more severe illness. Corticosteroid treatment may shorten illness duration in these patients.
Area of Science:
- Infectious Diseases
- Dermatology
- Pharmacology
Background:
- Human herpesvirus 6 (HHV6) positivity may worsen drug hypersensitivity syndrome (DHS) severity.
- Systemic corticosteroids are speculated to prolong DHS duration in HHV6-positive patients.
Purpose of the Study:
- To compare DHS severity in pediatric patients with and without HHV6 reactivation.
- To evaluate the efficacy of systemic corticosteroid treatment in HHV6-positive DHS patients.
Main Methods:
- Retrospective case series of 29 pediatric inpatients with DHS.
- Patients were tested for HHV6 and stratified by HHV6 status and corticosteroid treatment.
- Disease severity assessed by hospital length of stay (LOS), febrile days (Tfeb), and cessation of progression (CTP).
Main Results:
- HHV6-positive patients had significantly longer LOS, Tfeb, and CTP compared to HHV6-negative patients.
- Systemic corticosteroids were administered to all HHV6-positive and most HHV6-negative patients.
- In HHV6-negative patients, corticosteroids significantly reduced CTP and showed a trend toward reduced LOS and Tfeb.
Conclusions:
- HHV6 positivity is linked to more severe DHS in children.
- Systemic corticosteroids may reduce illness severity and duration in DHS patients, particularly in HHV6-negative cases.
Background:
Human herpesvirus (HHV)6 positivity in the context of drug hypersensitivity syndrome (DHS) may influence disease severity. Systemic corticosteroid treatment of those with DHS testing positive for HHV6 has been speculated to prolong the duration of disease.
Objectives:
To evaluate whether paediatric HHV6-positive patients with DHS develop a more severe illness than those without presumed reactivation, and to evaluate the response to systemic corticosteroid treatment.
Methods:
A retrospective case series of 29 paediatric inpatients treated for DHS and tested for HHV6 was undertaken. HHV6-positive and -negative patients were identified and stratified into groups treated or not treated with systemic corticosteroids to examine their disease severity on the basis of hospital length of stay (LOS), total number of febrile days (Tfeb) and days until cessation of progression (CTP).
Results:
Human herpesvirus6-positive patients had similar demographic characteristics to those of HHV6-negative patients, but had significantly longer hospital LOS (11·5 days vs. 5 days, P = 0·039), Tfeb (12·5 days vs. 3 days, P = 0·032) and CTP (4 days vs. 2 days, P = 0·014). All HHV6-positive patients and most (80%) of the HHV6-negative patients received systemic corticosteroids. Among the HHV6-negative patients, those who received corticosteroids showed significantly shorter CTP than those who did not (3 days vs. 2 days, P = 0·043). Additionally, there was a trend towards shorter hospital LOS and Tfeb among HHV6-negative patients who received corticosteroids vs. those who did not, although these differences were not statistically significant. The most common inciting drugs included trimethoprim-sulfamethoxazole (34%), phenytoin (10%) and amoxicillin (10%).
Conclusions:
Human herpesvirus6 positivity with DHS is associated with a more severe disease course. Treatment with systemic corticosteroids was associated with a trend towards reduced hospital LOS and Tfeb, and a significantly reduced number of days until cessation of progression.
Related Concept Videos
Drug Toxicity: Allergic Reactions
Allergic Drug Reactions
Hypersensitivities
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Hypersensitivity Reactions: Immune-Complex Reactions
Hypersensitivity Reactions: Cytolytic Reactions
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions

